Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist for the treatment of acute migraine attacks with or without aura. CGRP is a molecule involved in the migraine pathway. Ubrogepant targets CGRP receptors and can reduce the severity of migraine headaches. Ubrelvy only treats the symptoms of migraine headaches that have already started and is unable to prevent migraine attacks. It is intended only for use in adults above the age of 18.

Dosing

The treating doctor will determine the dosage regimen. The normal dose is usually one 50 mg or 100 mg tablet taken at the start of a migraine attack. It can be taken with a full glass of water, with or without food. If needed, a second dose may be taken at least 2 hours after the initial dose, but only if there was some significant relief of the pain from the initial dose. The maximum dose in 24 hours is 200 mg.

Caution:

A second tablet should not be taken if grapefruit or grapefruit juice has been consumed within the previous 24 hours or medications, including verapamil, cyclosporine, ciprofloxacin, fluconazole or fluvoxamine, have been taken inside that window.

If a higher dosage has been taken accidentally, or if a child has accidentally swallowed the medicine, go immediately to a doctor or a hospital emergency room along with the drug package.